Cargando…
Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial
BACKGROUND: Bleeding is the major risk of aspirin treatment, especially in the elderly. A consensus definition for clinically significant bleeding (CSB) in aspirin primary prevention trials is lacking in the literature. METHODS: This paper details the development, modification, application, and qual...
Autores principales: | Margolis, Karen L., Mahady, Suzanne E., Nelson, Mark R., Ives, Diane G., Satterfield, Suzanne, Britt, Carlene, Ekram, Saifuddin, Lockery, Jessica, Schwartz, Erin C., Woods, Robyn L., McNeil, John J., Wood, Erica M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022241/ https://www.ncbi.nlm.nih.gov/pubmed/30023457 http://dx.doi.org/10.1016/j.conctc.2018.05.015 |
Ejemplares similares
-
ASPREE SUB-STUDIES
por: Woods, Robyn L, et al.
Publicado: (2019) -
Overcoming challenges to data quality in the ASPREE clinical trial
por: Lockery, Jessica E., et al.
Publicado: (2019) -
Expanded statistical analysis plan for legacy and long-term effects of aspirin in the ASPREE-XT observational follow-up study of participants in the ASPREE randomized trial
por: Wolfe, Rory, et al.
Publicado: (2023) -
Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study
por: Robman, Liubov, et al.
Publicado: (2017) -
Baseline characteristics and age-related macular degeneration in participants of the “ASPirin in Reducing Events in the Elderly” (ASPREE)-AMD trial
por: Robman, Liubov D., et al.
Publicado: (2020)